Brief: Candel Therapeutics Presents Preclinical Data On Immunotherapy Candidate For Induction Of Tertiary Lymphoid Structures In Solid Tumors
09/04/2024 14:44
April 9 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS PRESENTS PRECLINICAL DATA AT AACR ON
IMMUNOTHERAPY CANDIDATE FOR INDUCTION OF TERTIARY LYMPHOID
STRUCTURES IN SOLID TUMORS
* CANDEL THERAPEUTICS:PRESENTATION ACCELERATES MILESTONE
RELATED
TO SECOND IMMUNOTHERAPY CANDIDATE BASED ON ENLIGHTEN DISCOVERY
PLATFORM
Source text for Eikon: ID:nGNX1yjDpD
Further company coverage: CADL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec